Form 8-K - Current report:
SEC Accession No. 0001493152-22-013253
Filing Date
2022-05-13
Accepted
2022-05-13 13:40:39
Documents
13
Period of Report
2022-05-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 35080
  Complete submission text file 0001493152-22-013253.txt   248449

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20220509.xsd EX-101.SCH 3722
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20220509_def.xml EX-101.DEF 26651
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20220509_lab.xml EX-101.LAB 36769
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20220509_pre.xml EX-101.PRE 25275
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5441
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 22921657
SIC: 2834 Pharmaceutical Preparations